Similar articles for PMID: 22381410

Year	Number of Results
2002	1
2003	6
2004	4
2005	6
2006	9
2007	13
2008	10
2009	13
2010	9
2011	19
2012	37
2013	26
2014	19
2015	3
2017	3
2018	1
2019	2
2020	5
2021	13
2022	8
2023	5
2024	1

1

ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.

Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA. Van den Abbeele AD, et al. J Nucl Med. 2012 Apr;53(4):567-74. doi: 10.2967/jnumed.111.094425. Epub 2012 Mar 1. J Nucl Med. 2012. PMID: 22381410 Free PMC article. Clinical Trial.

2

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.

Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD. Zukotynski K, et al. Cancer Imaging. 2014 Nov 12;14(1):30. doi: 10.1186/s40644-014-0030-0. Cancer Imaging. 2014. PMID: 25609545 Free PMC article. Clinical Trial.

3

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.

Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S. Prior JO, et al. J Clin Oncol. 2009 Jan 20;27(3):439-45. doi: 10.1200/JCO.2008.17.2742. Epub 2008 Dec 8. J Clin Oncol. 2009. PMID: 19064982 Clinical Trial.

4

[18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].

Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla JF, Sainz-Esteban A, Barragán J, Portilla-Quattrociocchi H, Carril JM. Banzo I, et al. Rev Esp Med Nucl. 2008 May-Jun;27(3):168-75. Rev Esp Med Nucl. 2008. PMID: 18570858 Clinical Trial. Spanish.

5

The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.

Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. Gayed I, et al. J Nucl Med. 2004 Jan;45(1):17-21. J Nucl Med. 2004. PMID: 14734662 Free article. Clinical Trial.

6

Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.

Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH, Raut CP. Tirumani SH, et al. Eur J Surg Oncol. 2014 Apr;40(4):420-8. doi: 10.1016/j.ejso.2013.10.021. Epub 2013 Nov 5. Eur J Surg Oncol. 2014. PMID: 24238762

7

Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.

Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H. Heinicke T, et al. Anticancer Res. 2005 Nov-Dec;25(6C):4591-4. Anticancer Res. 2005. PMID: 16334147 Free article.

8

Early Evaluation of Response Using ¹⁸F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib.

Farag S, Geus-Oei LF, van der Graaf WT, van Coevorden F, Grunhagen D, Reyners AKL, Boonstra PA, Desar I, Gelderblom H, Steeghs N. Farag S, et al. J Nucl Med. 2018 Feb;59(2):194-196. doi: 10.2967/jnumed.117.196642. Epub 2017 Sep 28. J Nucl Med. 2018. PMID: 28970330 Free article.

9

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.

Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. Choi H, et al. AJR Am J Roentgenol. 2004 Dec;183(6):1619-28. doi: 10.2214/ajr.183.6.01831619. AJR Am J Roentgenol. 2004. PMID: 15547201 Clinical Trial.

10

Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.

Jager PL, Gietema JA, van der Graaf WT. Jager PL, et al. Nucl Med Commun. 2004 May;25(5):433-8. doi: 10.1097/00006231-200405000-00002. Nucl Med Commun. 2004. PMID: 15100500 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

185 results

Results by year